T-cell acute lymphoblastic leukemia pediatric · 7 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cyclophosphamide, Cytarabine, Mercaptopurine, Pegaspargase, Vincristine N/A - intrathecal component Partial | — | R 15 025 | 71d | — | — | ~1 | ~R 15 025 indirect | — |
Cyclophosphamide, Cytarabine, Mercaptopurine, Nelarabine, Pegaspargase, Vincristine N/A - intrathecal component Partial | — | R 7 349 | 71d | — | — | ~1 | ~R 7 349 indirect | — |
Etoposide and TBI, then allo HSCT Variant #03 Partial | — | R 6 770 | — | — | — | ~1 | ~R 6 770 indirect | — |
Doxorubicin, Mercaptopurine, Methotrexate, Vincristine, Prednisone Variant #01 | — | R 3 838 | 42d | — | — | ~1 | ~R 3 838 indirect | — |
Doxorubicin, L-asparaginase, Mercaptopurine, Vincristine, Prednisone Partial | — | — | — | — | — | — | — | — |
Doxorubicin, L-asparaginase, Mercaptopurine, Methotrexate, Vincristine, Prednisone Partial | — | — | — | — | — | — | — | — |
L-asparaginase monotherapy Variant #01 Partial | — | — | 7d | — | — | ~20 | — | — |
7 of 7 regimens shown